Navigation Links
U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia
Date:6/25/2008

PRINCETON, N.J., Jun. 25 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) Advisory Committee on Cardiovascular and Renal Drugs voted to recommend the approval of tolvaptan, Otsuka Pharmaceutical Development & Commercialization, Inc.'s (OPDC) investigational treatment for patients with hyponatremia.

"Otsuka is pleased that the FDA Advisory Committee supports the potential approval of tolvaptan, an investigational selective V2-vasopressin receptor antagonist," said Taro Iwamoto, Ph.D., Chief Executive Officer, President and Chief Operating Officer of OPDC. "We believe tolvaptan, if approved by the FDA, has the potential to be an important treatment option for people with hyponatremia."

Hyponatremia, characterized by low concentrations of sodium in the blood, is a known predictor of mortality in patients with serious underlying illnesses.(i) Sodium is an important electrolyte that plays a role in blood pressure maintenance, muscle movement, and fluid regulation in and around cells.(ii) Approximately 3.2 million to 6.1 million people in the U.S. suffer from hyponatremia annually.(iii)

Tolvaptan is an investigational selective antagonist of the vasopressin V2 receptor, which is located predominantly in the kidney and plays a role in the regulation of fluid retention in the body. Vasopressin V2 antagonists work by selectively blocking the V2 receptor. This mechanism of action hinders water reabsorption and results in increased free water excretion (aquaresis), which is characterized by increased urine volume with no increase in urinary electrolyte excretion.

OPDC was established in 2007 by Otsuka America, Inc. (OAI). OPDC is wholly owned by OAI, which is the holding company for Otsuka Pharmaceutical Co., Ltd. (OPC) interests in the U.S. OAI is wholly owned by OPC.

About Otsuka Pharmaceutical Development & Commercialization, Inc.

Otsuka Pharmaceutical Development & Commercialization (OPDC) is involved in conductin
'/>"/>

SOURCE Otsuka Pharmaceutical Development & Commercialization,Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
3. Australian Therapeutics Goods Administration Approval for ActiPatch Achieved
4. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
5. Korean Food and Drug Administration Approval for ActiPatch Achieved
6. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
7. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
8. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
9. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
10. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
11. PPD Confirms Takedas NDA Filing of Alogliptin with U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Neurotrope, Inc. (OTCQB: ... conference call to provide an update on Company ... daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) or ... cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference replay ... through September 2, 2014 at (888) 203-1112 (U.S. ...
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... Report" report to their offering. This ... (SOFCs) in US$ Thousands. The report provides separate comprehensive analytics ... Europe , Asia-Pacific , and Rest ... period 2012 through 2020. Market data and analytics are derived ...
Breaking Biology Technology:Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... 11 The following is,GlaxoSmithKline,s (NYSE: ... by the,Institute for Clinical Evaluative Sciences (ICES) ... with,Diabetes"., GSK believes that the ICES ... database has significant limitations and generates misleading,conclusions ...
... today announced its,latest findings regarding the virus replikin ... analysis has found that the prevalence,of these sequences ... now have been found in China. These statistics ... linked to the lethality of,influenza viruses. When factored ...
... Dec. 11 Lucid, Inc., (http://www.lucid-tech.com ), a ... Dr. Colin Stahel as Director, Asia Pacific Region., ... for the newly created,position based on his extensive ... of experience in the development of medical,technology and ...
Cached Biology Technology:GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 2GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 3GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 4GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 5Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated 2Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region 2
(Date:8/20/2014)... Aug. 20, 2014  The second annual Biometrics ... Tampa, Florida on September ... Steven Rahman, Director, Technology and Strategy at Samsung, and ... The theme of this year,s event is Mobility ... "Biometrics UnPlugged: Mobility at the Crossroads ...
(Date:8/19/2014)... and Network-Level Science, , Imagine if we had the ... was responding to global changes in real time. Such ... multiple decades of information about ecological responses to environmental ... of different ecosystem types. , In fact, this ... Network, which will soon celebrate its 35th anniversary. , ...
(Date:8/19/2014)... have identified a biomarker strongly associated with basal-like ... resistant to many types of chemotherapy. The biomarker, ... for new therapeutics designed to treat this often ... taken from The Cancer Genome Atlas, molecular biologists ... powerful computational and bioinformatics techniques to detect patterns ...
Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2This week from AGU: Long-term ecological research, predicting cholera outbreaks 2Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... A new curriculum called The Great Diseases will ... high schools. The result of a collaboration between scientists ... the Boston Public Schools, the curriculum presents current threats ... studies. Funded by a grant from the National Institutes ...
... Cory, the former director of the Walter and Eliza ... been named the recipient of the 2009 Pearl Meister ... prize, created to recognise the accomplishments of outstanding female ... 5 November. The prize was founded by Rockefeller ...
... someday help clean up the earth. Converting methane ... prevent the potent greenhouse gas from entering the atmosphere. ... hydrogen source for fuel cells and yield other industrial ... in the laboratory, rests in identifying the starter link ...
Cached Biology News:Grant brings real-world science to Boston classrooms 2Grant brings real-world science to Boston classrooms 3Professor Suzanne Cory awarded 2009 Pearl Meister Greengard Prize 2RIT scientist shines laser light on methane in pursuit of clean fuel 2